22:07 on August 8, 2019, Immuron Ltd (IMRN.us) shares changed, and the share price fell 5.26%. As of press time, the stock was trading at US $3.06 per share, with a turnover of 4568 shares, a turnover rate of 0.11% and an amplitude of 5.88%.

The latest 2018-12-31 data show that the stock achieved operating income of $708526.00, net profit of-$1.15 million, earnings per share of-$0.34, gross profit of $538951.22, and price-to-earnings ratio of-5.39 times.

In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.

The biotech industry in which Immuron Ltd shares are located rose 0.74 per cent as a whole. Among its related stocks, G1 Therapeutics Inc, Vistagen Therapeutics Inc and Dare Bioscience Inc rose significantly, while Hemispherx Biopharma Inc, Dare Bioscience Inc and Clovis Oncology Inc were more active, with turnover rates of 30.52%, 8.33% and 4.00%, respectively. The related stocks with larger amplitudes were Vistagen Therapeutics Inc, Dare Bioscience Inc and Morphic Holding Inc, with amplitudes of 29.26%, 24.27% and 21.20%, respectively.

About Immuron Ltd: Immuron is a biopharmaceutical company that develops polyclonal antibodies for the treatment and prevention of diseases. Its products include Travelan, IMM-124E for the treatment of NASH, and IMM-529 for Clostridium labile infection.

(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )